|The following article features coverage from the ASCO Genitourinary Cancers Symposium 2022. Click here to read more of Cancer Therapy Advisor’s conference coverage.|
Baseline cytokine levels correlate with oncologic and survival outcomes in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab and may prove useful for prognosis, investigators reported at the ASCO Genitourinary Cancers Symposium 2022.
Investigators examined a panel of 14 plasma cytokines and proteins in 40 responders and 40 progressors treated with nivolumab in the NIVOREN GETUG-AFU 26 study. The International Metastatic RCC Database Consortium (IMDC) risk score was good, intermediate, and poor in 11.3%, 56.3%, and 32.5%, respectively.
At 12 months, overall survival (OS) was 67.3%. Median OS was not yet reached after a median follow-up of 21.2 months. Median progression-free survival (PFS) was 3.8 months.
Among the 14 cytokines, higher levels of vascular endothelial growth factor (VEGF) and interleukin (IL)-6, IL-7, and IL-8 at baseline were significantly associated with 2.4-, 2.4-, 2.4-, and 2.8-fold increased mortality risk, Lucia Carril-Ajuria, MD, of Hospital Universitario 12 de Octubre and Instituto de Investigación, Madrid, Spain, reported on behalf of her team.
Higher levels of VEGF and IL-8 were also significantly associated with 2.0- and 2.5-fold worse PFS, respectively, and worse objective response rate (ORR).
Only higher levels of 4-1BB were significantly associated with a 61% improved OS, Dr Carril-Ajuria emphasized.
The investigators are currently validating these findings within the entire NIVOREN study population.
Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Read more of Cancer Therapy Advisor’s coverage of ASCO GU 2022 by visiting the conference page.
Carril L, Naigeon M, Dalban C, et al. The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study. Presented at: ASCO GU 2022; February 17-19, 2022. Abstract 379.
This article originally appeared on Renal and Urology News